PubMed:33745264 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":178},"obj":"Sentence"},{"id":"T2","span":{"begin":179,"end":190},"obj":"Sentence"},{"id":"T3","span":{"begin":191,"end":327},"obj":"Sentence"},{"id":"T4","span":{"begin":328,"end":428},"obj":"Sentence"},{"id":"T5","span":{"begin":429,"end":437},"obj":"Sentence"},{"id":"T6","span":{"begin":438,"end":796},"obj":"Sentence"},{"id":"T7","span":{"begin":797,"end":879},"obj":"Sentence"},{"id":"T8","span":{"begin":880,"end":965},"obj":"Sentence"},{"id":"T9","span":{"begin":966,"end":974},"obj":"Sentence"},{"id":"T10","span":{"begin":975,"end":1004},"obj":"Sentence"},{"id":"T11","span":{"begin":1005,"end":1088},"obj":"Sentence"},{"id":"T12","span":{"begin":1089,"end":1232},"obj":"Sentence"},{"id":"T13","span":{"begin":1233,"end":1288},"obj":"Sentence"},{"id":"T14","span":{"begin":1289,"end":1394},"obj":"Sentence"},{"id":"T15","span":{"begin":1395,"end":1422},"obj":"Sentence"},{"id":"T16","span":{"begin":1423,"end":1453},"obj":"Sentence"},{"id":"T17","span":{"begin":1454,"end":1492},"obj":"Sentence"},{"id":"T18","span":{"begin":1493,"end":1550},"obj":"Sentence"},{"id":"T19","span":{"begin":1551,"end":1562},"obj":"Sentence"},{"id":"T20","span":{"begin":1563,"end":1665},"obj":"Sentence"},{"id":"T21","span":{"begin":1666,"end":1925},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":178},"obj":"Sentence"},{"id":"T2","span":{"begin":179,"end":190},"obj":"Sentence"},{"id":"T3","span":{"begin":191,"end":327},"obj":"Sentence"},{"id":"T4","span":{"begin":328,"end":428},"obj":"Sentence"},{"id":"T5","span":{"begin":429,"end":437},"obj":"Sentence"},{"id":"T6","span":{"begin":438,"end":796},"obj":"Sentence"},{"id":"T7","span":{"begin":797,"end":879},"obj":"Sentence"},{"id":"T8","span":{"begin":880,"end":965},"obj":"Sentence"},{"id":"T9","span":{"begin":966,"end":974},"obj":"Sentence"},{"id":"T10","span":{"begin":975,"end":1004},"obj":"Sentence"},{"id":"T11","span":{"begin":1005,"end":1088},"obj":"Sentence"},{"id":"T12","span":{"begin":1089,"end":1232},"obj":"Sentence"},{"id":"T13","span":{"begin":1233,"end":1288},"obj":"Sentence"},{"id":"T14","span":{"begin":1289,"end":1394},"obj":"Sentence"},{"id":"T15","span":{"begin":1395,"end":1422},"obj":"Sentence"},{"id":"T16","span":{"begin":1423,"end":1453},"obj":"Sentence"},{"id":"T17","span":{"begin":1454,"end":1492},"obj":"Sentence"},{"id":"T18","span":{"begin":1493,"end":1550},"obj":"Sentence"},{"id":"T19","span":{"begin":1551,"end":1562},"obj":"Sentence"},{"id":"T20","span":{"begin":1563,"end":1665},"obj":"Sentence"},{"id":"T21","span":{"begin":1666,"end":1925},"obj":"Sentence"}],"text":"The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study.\nBACKGROUND: Concerns exist regarding the pro-oxidant and inflammatory potential of intravenous (IV) iron due to labile plasma iron (LPI) generation. This IRON-CKD trial compared the effects of different IV irons on oxidative stress and inflammation.\nMETHODS: In this randomized open-label explorative single-center study in the United Kingdom, non-dialysis-dependent chronic kidney disease (CKD) patients with iron deficiency were randomized (1:1:1:1) to receive a single infusion of 200 mg iron dextran, or 200 mg iron sucrose (IS), or 200 mg or 1,000 mg ferric derisomaltose (FDI) and were followed up for 3 months. The primary outcomes measured were induction of oxidative stress and inflammation. Secondarily, efficacy, vascular function, quality of life, and safety were monitored.\nRESULTS: Forty patients were enrolled. No significant rise in oxidative stress existed, regardless of preparation or dose. There was a significant rise in LPI with 1,000 mg FDI at 2 hours that normalized within a week, not impacting oxidative stress or inflammation. A delayed rise in C-reactive protein was noted with IS. High-dose FDI produced a sustained serum ferritin increase (mean ± standard error of the mean of predose: 69.1 ± 18.4 μg/L, 3 months: 271.0 ± 83.3 μg/L; p = 0.007). Hemoglobin remained stable throughout. No adverse drug reactions were recorded during the study.\nCONCLUSION: A single dose of IV iron in CKD patients does not trigger oxidative stress or inflammation biomarkers. Third-generation IV irons have a reassuring safety profile, and high-dose FDI produced a sustained serum ferritin rise and more efficient iron repletion, with no significant pro-oxidant or inflammatory signals when compared to a lower dose and other IV irons."}